AU2007255110B8 - Circulating tumor cell assay - Google Patents

Circulating tumor cell assay Download PDF

Info

Publication number
AU2007255110B8
AU2007255110B8 AU2007255110A AU2007255110A AU2007255110B8 AU 2007255110 B8 AU2007255110 B8 AU 2007255110B8 AU 2007255110 A AU2007255110 A AU 2007255110A AU 2007255110 A AU2007255110 A AU 2007255110A AU 2007255110 B8 AU2007255110 B8 AU 2007255110B8
Authority
AU
Australia
Prior art keywords
igf
antibody
sample
patient
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007255110A
Other languages
English (en)
Other versions
AU2007255110A1 (en
AU2007255110B2 (en
AU2007255110A8 (en
Inventor
David Allen Chianese
Mark Carle Connelly
Antonio Gualberto
Carrie Lynn Melvin
Madeline I. Repollet
Luisa Maria Roberts
Leonardus Wendelinus Mathias Marie Terstappen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Janssen Diagnostics LLC
Original Assignee
Pfizer Products Inc
Veridex LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc, Veridex LLC filed Critical Pfizer Products Inc
Publication of AU2007255110A1 publication Critical patent/AU2007255110A1/en
Assigned to PFIZER PRODUCTS INC., VERIDEX, LLC reassignment PFIZER PRODUCTS INC. Amend patent request/document other than specification (104) Assignors: PFIZER PRODUCTS INC.
Application granted granted Critical
Publication of AU2007255110B2 publication Critical patent/AU2007255110B2/en
Publication of AU2007255110B8 publication Critical patent/AU2007255110B8/en
Publication of AU2007255110A8 publication Critical patent/AU2007255110A8/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4742—Keratin; Cytokeratin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4745—Insulin-like growth factor binding protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hospice & Palliative Care (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2007255110A 2006-06-02 2007-05-29 Circulating tumor cell assay Ceased AU2007255110B8 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81081106P 2006-06-02 2006-06-02
US60/810,811 2006-06-02
PCT/IB2007/001483 WO2007141626A1 (en) 2006-06-02 2007-05-29 Circulating tumor cell assay

Publications (4)

Publication Number Publication Date
AU2007255110A1 AU2007255110A1 (en) 2007-12-13
AU2007255110B2 AU2007255110B2 (en) 2014-03-20
AU2007255110B8 true AU2007255110B8 (en) 2014-04-10
AU2007255110A8 AU2007255110A8 (en) 2014-04-10

Family

ID=38476880

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007255110A Ceased AU2007255110B8 (en) 2006-06-02 2007-05-29 Circulating tumor cell assay

Country Status (19)

Country Link
US (4) US8940493B2 (https=)
EP (1) EP2027470B1 (https=)
JP (1) JP4943504B2 (https=)
KR (3) KR20140052081A (https=)
CN (1) CN101600966B (https=)
AU (1) AU2007255110B8 (https=)
BR (1) BRPI0712225A8 (https=)
CA (1) CA2653745C (https=)
DK (1) DK2027470T3 (https=)
ES (1) ES2397971T3 (https=)
IL (1) IL195577A (https=)
MX (1) MX2008015425A (https=)
NZ (1) NZ573187A (https=)
PL (1) PL2027470T3 (https=)
PT (1) PT2027470E (https=)
RU (1) RU2429486C2 (https=)
SI (1) SI2027470T1 (https=)
WO (1) WO2007141626A1 (https=)
ZA (1) ZA200810203B (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2623125A1 (en) 2005-09-20 2007-03-29 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2011050103A1 (en) * 2009-10-21 2011-04-28 The Scripps Research Institute Method of using non-rare cells to detect rare cells
NZ573187A (en) 2006-06-02 2011-11-25 Pfizer Prod Inc Circulating tumor cell assay for predicting efficacy of 1gf-1r antagonist therapy
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
JP2010540960A (ja) 2007-10-03 2010-12-24 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド インスリン様成長因子−１受容体キナーゼ阻害剤に対する抗癌反応を予測する生物学的マーカー
WO2009045389A2 (en) 2007-10-03 2009-04-09 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20090258365A1 (en) * 2008-03-25 2009-10-15 Terstappen Leon W M M METHOD FOR DETECTING IGF1R/Chr 15 in CIRCULATING TUMOR CELLS USING FISH
NZ597692A (en) 2008-12-12 2013-08-30 Boehringer Ingelheim Int Anti-IGF antibodies
WO2011083391A2 (en) * 2010-01-05 2011-07-14 Pfizer Inc. Biomarkers for anti-igf-ir cancer therapy
JP5960146B2 (ja) * 2010-10-14 2016-08-02 ジャンセン ダイアグノスティックス，エルエルシー 多特異性捕捉試薬及び混合検出試薬を用いる膵臓患者の循環腫瘍細胞を検出する方法及びキット
AU2012209329A1 (en) * 2011-01-24 2013-09-12 Epic Sciences, Inc. Methods for obtaining single cells and applications of single cell omics
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013013222A1 (en) * 2011-07-21 2013-01-24 Veridex, Llc Assay to capture and detect circulating multiple myeloma cells from blood
WO2013036620A1 (en) * 2011-09-06 2013-03-14 Becton, Dickinson And Company Methods and compositions for cytometric detection of rare target cells in a sample
AU2013302867A1 (en) 2012-08-13 2015-02-26 The Regents Of The University Of California Methods and systems for detecting biological components
PL2903691T3 (pl) * 2012-10-05 2019-10-31 Hoffmann La Roche Sposoby diagnozowania i leczenia nieswoistego zapalenia jelit
EP4075478A1 (en) * 2012-10-26 2022-10-19 Fluidigm Canada Inc. Sample and method of sample preparation
US9396532B2 (en) * 2012-11-15 2016-07-19 Siemens Healthcare Diagnostics, Inc. Cell feature-based automatic circulating tumor cell detection
CA2895791A1 (en) 2013-01-25 2014-07-31 Xcell Biosciences, Inc. Methods, compositions, kits, and systems for selective enrichment of target cells
US20150233932A1 (en) * 2013-02-19 2015-08-20 Ching-Ping Tseng Methods, Systems, and Compositions for Enrichment of Rare Cells
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
EP3683321B1 (en) * 2013-10-21 2021-12-08 The General Hospital Corporation Methods relating to circulating tumor cell clusters and the treatment of cancer
CN103630440A (zh) * 2013-11-28 2014-03-12 武汉大学 一种循环肿瘤细胞的富集方法
US10527624B2 (en) 2014-01-27 2020-01-07 Epic Sciences, Inc. Circulating tumor cell diagnostics for prostate cancer biomarkers
AU2015215008B2 (en) * 2014-02-05 2019-11-28 Fujirebio Diagnostics Ab Composition and method for detecting malignant neoplastic disease
EP3108246B1 (en) 2014-02-21 2019-10-09 Epic Sciences, Inc. Methods for analyzing rare circulating cells
CN103940997B (zh) * 2014-03-21 2017-01-04 上海柏慧康生物科技有限公司 一种乳腺癌循环肿瘤细胞检测系统及试剂盒
KR101656037B1 (ko) * 2014-04-30 2016-09-08 울산과학기술원 희소 세포 분리장치, 희소 세포 분리 방법 및 이를 이용한 희소 세포 검출 방법
US10697007B2 (en) 2014-06-27 2020-06-30 The Regents Of The University Of California PCR-activated sorting (PAS)
WO2016033103A1 (en) * 2014-08-25 2016-03-03 Creatv Microtech, Inc. Use of circulating cell biomarkers in the blood for detection and diagnosis of diseases and methods of isolating them
CN104345052B (zh) * 2014-09-29 2017-10-20 南通市肿瘤医院 一种荧光负染法检测活细胞的方法
US10434507B2 (en) 2014-10-22 2019-10-08 The Regents Of The University Of California High definition microdroplet printer
EP3253479B1 (en) 2015-02-04 2022-09-21 The Regents of The University of California Sequencing of nucleic acids via barcoding in discrete entities
AU2016252771B2 (en) * 2015-04-22 2021-12-16 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
KR101701618B1 (ko) 2015-06-23 2017-02-13 국립암센터 전도성 고분자를 이용한 세포 유리 ｄｎａ 검출용 구조체 및 이의 용도
RU2616532C1 (ru) * 2015-12-28 2017-04-17 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ оценки чувствительности опухоли к проводимой химиотерапии больных местно-распространенным раком молочной железы
KR102130872B1 (ko) 2016-04-27 2020-07-06 주식회사 엘지화학 고체 시료의 수분 측정 장치, 고체 시료 수분 함량 측정 방법 및 이미드화율 분석 방법
EP3497228A4 (en) 2016-08-10 2020-05-27 The Regents of The University of California MULTI-DISPLACEMENT AMPLIFICATION AND PCR COMBINED IN AN EMULSION MICRO DROPLET
CA3047328A1 (en) 2016-12-21 2018-06-28 The Regents Of The University Of California Single cell genomic sequencing using hydrogel based droplets
RU2756717C2 (ru) 2017-04-05 2021-10-04 Филип Моррис Продактс С.А. Токоприемник для использования с индукционно нагреваемым устройством, генерирующим аэрозоль, или системой, генерирующей аэрозоль
US10501739B2 (en) 2017-10-18 2019-12-10 Mission Bio, Inc. Method, systems and apparatus for single cell analysis
EP3540631A1 (de) 2018-03-15 2019-09-18 Siemens Healthcare GmbH In-vitro-verfahren zum markierungsfreien bestimmen eines zelltyps einer weissen blutzelle
CN109406245A (zh) * 2018-09-12 2019-03-01 中国辐射防护研究院 一种电子线照射对小鼠igf相关蛋白表达影响的检测方法
AU2020280104A1 (en) 2019-05-22 2022-01-20 Mission Bio, Inc. Method and apparatus for simultaneous targeted sequencing of DNA, RNA and protein
US11667954B2 (en) 2019-07-01 2023-06-06 Mission Bio, Inc. Method and apparatus to normalize quantitative readouts in single-cell experiments
WO2023188078A1 (ja) 2022-03-30 2023-10-05 日本たばこ産業株式会社 非燃焼加熱型の香味吸引物品に用いる香味シート
EP4646208A1 (en) 2023-01-06 2025-11-12 Ideaya Biosciences, Inc. Treatment of er+ breast cancer comprising homologous recombination deficiency using parg inhibitor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018757A2 (en) * 2001-08-23 2003-03-06 Immunivest Corporation Stabilization of cells and biological specimens for analysis
WO2003065042A1 (en) * 2001-02-16 2003-08-07 Immunivest Corporation Methods and reagents for the rapid and efficient isolation of circulating cancer cells
WO2005016967A2 (en) * 2003-08-13 2005-02-24 Pfizer Products Inc. Modified human igf-1r antibodies
WO2006008639A1 (en) * 2004-07-16 2006-01-26 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4551435A (en) * 1983-08-24 1985-11-05 Immunicon, Inc. Selective removal of immunospecifically recognizable substances from solution
US4795698A (en) * 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US4925788A (en) * 1986-10-24 1990-05-15 Immunicon Corporation Immunoassay system and procedure based on precipitin-like interaction between immune complex and Clq or other non-immunospecific factor
US5108933A (en) * 1988-09-16 1992-04-28 Immunicon Corporation Manipulation of colloids for facilitating magnetic separations
US5200084A (en) * 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
CN1153064C (zh) * 1996-04-05 2004-06-09 约翰斯·霍普金斯大学 富集稀少细胞的方法
US20010018192A1 (en) * 1998-02-12 2001-08-30 Terstappen Leon W.M.M. Labeled cells for use as an internal functional control in rare cell detection assays
BR9907852A (pt) * 1998-02-12 2000-10-24 Immunivest Corp Processos para detectar e enumerar células raras e cancerosas em uma população celular mista, para diagnosticar câncer de estágio precoce em um paciente de teste, para determinar a probabilidade de recorrência de câncer em um paciente humano anteriormente tratado de câncer, para distinguir um carcinoma confinado ao órgão de um carcinoma com propriedades metastáticas, para acompanhar a situação de remissão em um paciente humano com câncer que passa pelo tratamento de terapia contra o câncer e para aumentar quantidades de células epiteliais circulantes em uma amostra de sangue, partìcula magnética revestida, composição, conjuntos de teste para avaliar uma amostra de paciente quanto a presença de células raras circulantes, quanto a presença de células de tumor circulantes, quanto a presença de células de câncer de mama circulantes, quanto a presença de células de câncer de próstata circulantes, quanto a presença de células de câncer de cólon circulantes, quanto a presença de células de câncer de bexiga circulantes e para monitorar um paciente quanto a recorrência de câncer, e, fração de sangue periférico enriquecido quanto a células neoplásticas circulantes
US20020172987A1 (en) * 1998-02-12 2002-11-21 Terstappen Leon W.M.M. Methods and reagents for the rapid and efficient isolation of circulating cancer cells
CA2350692A1 (en) 1998-10-29 2000-05-11 Cell Works Diagnostics, Inc. Multiple marker characterization of single cells
US6960449B2 (en) * 1999-02-10 2005-11-01 Cell Works Diagnostics, Inc. Class characterization of circulating cancer cells isolated from body fluids and methods of use
JP2001041959A (ja) * 1999-05-24 2001-02-16 Toray Ind Inc 癌細胞検出システムおよび癌細胞検出キット
IL148175A0 (en) 1999-08-18 2002-09-12 Gen Hospital Corp Methods, compositions and kits for promoting recovery from damage to the central nervous system
US7537938B2 (en) * 2000-04-28 2009-05-26 Monogram Biosciences, Inc. Biomarker detection in circulating cells
NZ537458A (en) * 2001-01-23 2007-02-23 Primagen Holding B Means and methods for treatment evaluation
US7863012B2 (en) * 2004-02-17 2011-01-04 Veridex, Llc Analysis of circulating tumor cells, fragments, and debris
US6670142B2 (en) * 2001-10-26 2003-12-30 The Regents Of The University Of California Method for screening combinatorial bead library, capturing cells from body fluids, and ligands for cancer cells
SI1461359T1 (sl) * 2002-01-18 2007-06-30 Pf Medicament Nova anti IGF-IR protitelesa in njihova uporaba
US20040229294A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB surface receptor complexes as biomarkers
US20060045881A1 (en) * 2004-08-26 2006-03-02 Board Of Regents, The University Of Texas System Anti-cancer vaccines
WO2006041453A1 (en) 2004-09-30 2006-04-20 Immunivest Corporation Circulating tumor cells (ctc’s): apoptotic assessment in prostate cancer patients
EP1861509B1 (en) 2005-03-14 2015-09-09 Janssen Diagnostics, LLC A method for predicting progression free and overall survival at each follow-up time point during therapy of metastatic breast cancer patients using circulating tumor cells
US20070037173A1 (en) * 2005-08-12 2007-02-15 Allard Jeffrey W Circulating tumor cells (CTC's): early assessment of time to progression, survival and response to therapy in metastatic cancer patients
NZ573187A (en) 2006-06-02 2011-11-25 Pfizer Prod Inc Circulating tumor cell assay for predicting efficacy of 1gf-1r antagonist therapy
PL2210080T3 (pl) * 2007-10-24 2015-06-30 Biomarker Strategies Llc Ulepszone sposoby i urządzenia do analizy komórkowej

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003065042A1 (en) * 2001-02-16 2003-08-07 Immunivest Corporation Methods and reagents for the rapid and efficient isolation of circulating cancer cells
WO2003018757A2 (en) * 2001-08-23 2003-03-06 Immunivest Corporation Stabilization of cells and biological specimens for analysis
WO2005016967A2 (en) * 2003-08-13 2005-02-24 Pfizer Products Inc. Modified human igf-1r antibodies
WO2006008639A1 (en) * 2004-07-16 2006-01-26 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HAYES, DF et al. International Journal of Oncology, November 2002, Vol.21, No.5, pages 1111-1117. *
KAGAN, M. et al. Journal of Clinincal Ligand Assay, March 2002, Vol.25, No.1, pages 104-110. *
LARSON, CJ et al. Cytometry A, November 2004, Vol.62, No.1, pages 46-53. *
MORENO, JG et al. Urology, April 2005, Vol.65, No.4, pages 713-718 *
RAO, C. et al. Proceedings of the Annual Meeting of the American Association for Cancer Research, March 2004, Vol.45, page 763 *

Also Published As

Publication number Publication date
ES2397971T3 (es) 2013-03-12
MX2008015425A (es) 2008-12-12
CN101600966A (zh) 2009-12-09
KR20130091788A (ko) 2013-08-19
CA2653745C (en) 2013-11-19
JP4943504B2 (ja) 2012-05-30
NZ573187A (en) 2011-11-25
US8940493B2 (en) 2015-01-27
RU2008147415A (ru) 2010-06-10
KR20090023423A (ko) 2009-03-04
PL2027470T3 (pl) 2013-03-29
US20180011103A1 (en) 2018-01-11
EP2027470A1 (en) 2009-02-25
BRPI0712225A8 (pt) 2019-01-22
EP2027470B1 (en) 2012-11-21
BRPI0712225A2 (pt) 2012-07-24
DK2027470T3 (da) 2013-02-04
ZA200810203B (en) 2020-05-27
US20100028915A1 (en) 2010-02-04
CA2653745A1 (en) 2007-12-13
KR20140052081A (ko) 2014-05-02
IL195577A0 (en) 2009-09-01
US20200191793A1 (en) 2020-06-18
WO2007141626A1 (en) 2007-12-13
IL195577A (en) 2012-12-31
AU2007255110A1 (en) 2007-12-13
CN101600966B (zh) 2014-07-02
JP2009539097A (ja) 2009-11-12
RU2429486C2 (ru) 2011-09-20
PT2027470E (pt) 2013-01-28
AU2007255110B2 (en) 2014-03-20
HK1137509A1 (en) 2010-07-30
AU2007255110A8 (en) 2014-04-10
SI2027470T1 (sl) 2013-01-31
WO2007141626A8 (en) 2009-01-08
KR101467136B1 (ko) 2014-12-01
US20150177252A1 (en) 2015-06-25

Similar Documents

Publication Publication Date Title
AU2007255110B8 (en) Circulating tumor cell assay
Ludovini et al. Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival
Smerage et al. Monitoring apoptosis and Bcl-2 on circulating tumor cells in patients with metastatic breast cancer
Lüftner et al. Serum HER-2/neu in the management of breast cancer patients
Cabioglu et al. Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow
CA2623445A1 (en) Comprehensive diagnostic testing procedures for personalized anticancer chemotherapy (pac)
US7794960B2 (en) Predictive biomarkers in cancer therapy
Mascaux et al. EGFR protein expression in non–small cell lung cancer predicts response to an EGFR tyrosine kinase inhibitor—A novel antibody for immunohistochemistry or AQUA technology
Ryu et al. Impact of serum HER2 levels on survival and its correlation with clinicopathological parameters in women with breast cancer
Milman et al. Medullary thyroid cancer that stains negative for CA 19-9 has decreased metastatic potential
Nagaiah et al. Circulating tumor cells in the management of breast cancer
Nanguzgambo et al. Immunochemistry and lung cancer: application in diagnosis, prognosis and targeted therapy
HK1137509B (en) Circulating tumor cell assay
Kong et al. Serum HER2 as a response indicator to various chemotherapeutic agents in tissue HER2 positive metastatic breast cancer
Słodkowska et al. Digital pathology in personalized cancer therapy
Kim et al. Establishment for reference range of serum HER-2/neu in Korean healthy women
Herrspiegel et al. serUM-Px Liquid Biopsies Predicts Mortality in Uveal Melanoma
JP2023177246A (ja) 乳がん患者の予後を予測する方法
Ma et al. Study on serum HER2 extracellular domain expression in early stage breast cancer patients
Müller Sentinel Lymph
van Halteren et al. Early Breast Cancer Agressiveness does not Differ Between Insulin-Sensitive and Insulin-Resistant Postmenopausal Non-Diabetic Women
Ryu et al. Evaluation of serum HER-2/neu in breast cancer patients: correlation with clinicopathological parameters and survival

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 23 , NO 1 , PAGE(S) 6092 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME PFIZER PRODUCTS INC.; VERIDEX, LLC, APPLICATION NO. 2007255110, UNDER INID (72) CORRECT THE CO-INVENTOR TO CONNELLY, MARK CARLE

Free format text: IN VOL 28 , NO 11 , PAGE(S) 1551 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME PFIZER PRODUCTS INC.; VERIDEX, LLC, APPLICATION NO. 2007255110, UNDER INID (72) CORRECT THE CO-INVENTOR TO CONNELLY, MARK CARLE

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired